{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:39:22Z","timestamp":1792791562560,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009391","name":"Kafkas \u00dcniversitesi","doi-asserted-by":"publisher","award":["2023-TS-107"],"award-info":[{"award-number":["2023-TS-107"]}],"id":[{"id":"10.13039\/501100009391","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.neuropharm.2026.111173","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T06:44:30Z","timestamp":1788331470000},"page":"111173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Neuroprotective effects of chitosan nanoparticle-loaded orientin in a 6-OHDA-induced Parkinson's disease experimental model in rats"],"prefix":"10.1016","volume":"301","author":[{"given":"Volkan","family":"Gelen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cemil","family":"Bayram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adem","family":"Kara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz","family":"Tekiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Ye\u015filda\u011f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"33","key":"10.1016\/j.neuropharm.2026.111173_bib2","first-page":"2565","article-title":"Antioxidant effects of the orientin and vitexin in Trollius chinensis Bunge in D-galactose-aged mice","volume":"7","author":"An","year":"2012","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.neuropharm.2026.111173_bib3","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1152\/ajpheart.00406.2014","article-title":"Dysautonomias in Parkinson's disease: cardiovascular changes and autonomic modulation in conscious rats after infusion of bilateral 6-OHDA in substantia nigra","volume":"308","author":"Ariza","year":"2015","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111173_bib5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0939-6411(03)00161-9","article-title":"Structure and interactions in chitosan hydrogels formed by complexation or aggregation for biomedical applications","volume":"57","author":"Berger","year":"2004","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.neuropharm.2026.111173_bib6","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1042\/BST0351127","article-title":"Chronic microglial activation and progressive dopaminergic neurotoxicity","volume":"35","author":"Block","year":"2007","journal-title":"Biochem. Soc. Trans."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111173_bib7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO;2-4","article-title":"Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers","volume":"63","author":"Calvo","year":"1997","journal-title":"J. Appl. Polym. Sci."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111173_bib8","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3109\/21691401.2014.948548","article-title":"Advances in preparation and characterization of chitosan nanoparticles for therapeutics","volume":"44","author":"Chandra Hembram","year":"2016","journal-title":"Artif. Cells, Nanomed. Biotechnol."},{"key":"10.1016\/j.neuropharm.2026.111173_bib9","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.drudis.2019.05.003","article-title":"The current status of pharmacotherapy for the treatment of Parkinson's disease: transition from single-target to multitarget therapy","volume":"24","author":"Cheong","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.neuropharm.2026.111173_bib11","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1046\/j.1460-9568.2002.01938.x","article-title":"Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging","volume":"15","author":"Cicchetti","year":"2002","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2026.111173_bib13","first-page":"573","article-title":"Parkinson's disease: a short story of 200 years","volume":"34","author":"Cuenca","year":"2019","journal-title":"Histol. Histopathol."},{"issue":"2","key":"10.1016\/j.neuropharm.2026.111173_bib14","first-page":"217","article-title":"Kinetic modeling on drug release from controlled drug delivery systems","volume":"68","author":"Dash","year":"2011","journal-title":"Acta Pol. Pharm."},{"key":"10.1016\/j.neuropharm.2026.111173_bib15","doi-asserted-by":"crossref","unstructured":"Dauer,W.;Przedborski,S.Parkinson\u2019sdisease: Mechanismsandmodels. Neuron2003,39,889\u2013909.","DOI":"10.1016\/S0896-6273(03)00568-3"},{"key":"10.1016\/j.neuropharm.2026.111173_bib17","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1111\/ejn.15242","article-title":"Nuclear factor-kappa B (NF-\u03baB) in pathophysiology of Parkinson disease: diverse patterns and mechanisms contributing to neurodegeneration","volume":"54","author":"Dolatshahi","year":"2021","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2026.111173_bib18","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","article-title":"Global, regional, and national burden of Parkinson's disease, 1990\u20132016: a systematic analysis for the global Burden of Disease Study 2016","volume":"17","author":"Dorsey","year":"2018","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111173_bib19","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s12640-021-00450-x","article-title":"Neuroprotective Effects of Resveratrol in in vivo and in vitro Experimental Models of Parkinson's Disease: a Systematic Review","volume":"40","author":"Dos Santos","year":"2022","journal-title":"Neurotox. Res."},{"issue":"3","key":"10.1016\/j.neuropharm.2026.111173_bib20","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1055\/a-1960-3092","article-title":"Curcumin-Loaded chitosan nanoparticle preparation and its protective effect on celecoxib-induced toxicity in rat isolated cardiomyocytes and Mitochondria","volume":"73","author":"Ebrahimi","year":"2023","journal-title":"Drug Res."},{"issue":"3","key":"10.1016\/j.neuropharm.2026.111173_bib21","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1089\/ars.2008.2228","article-title":"Parkinson-linked genes and toxins that affect neuronal cell death through the Bcl-2 family","volume":"11","author":"Ethell","year":"2009","journal-title":"Antioxidants Redox Signal."},{"key":"10.1016\/j.neuropharm.2026.111173_bib23","doi-asserted-by":"crossref","first-page":"260","DOI":"10.2174\/1570159X13666151030102718","article-title":"Anti OxidantsinParkinson\u2019sdiseasetherapy: acritical point of view","volume":"14","author":"Filograna","year":"2016","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2026.111173_bib24","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1021\/cr980450y","article-title":"Structural insight into the aromatic amino acid hydroxylases and their disease-related mutant forms","volume":"99","author":"Flatmark","year":"1999","journal-title":"Chem. Rev."},{"key":"10.1016\/j.neuropharm.2026.111173_bib25","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0169-328X(96)00018-6","article-title":"Expression of dopamine transporter mRNA and its binding site in fetal nigral cells transplanted into the striatum of 6-OHDA lesioned rat","volume":"39","author":"Fujita","year":"1996","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/j.neuropharm.2026.111173_bib27","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.intimp.2018.03.013","article-title":"Orientin and neuropathic pain in rats with spinal nerve ligation","volume":"58","author":"Guo","year":"2018","journal-title":"Int. Immunopharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2026.111173_bib28","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF02741387","article-title":"Tyrosine hydroxylase and Parkinson'S disease","volume":"16","author":"Haavik","year":"1998","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2026.111173_bib29","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1073\/pnas.040556597","article-title":"Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease","volume":"97","author":"Hartmann","year":"2000","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.neuropharm.2026.111173_bib30","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.amjmed.2019.03.001","article-title":"Parkinson's disease and parkinsonism","volume":"132","author":"Hayes","year":"2019","journal-title":"Am. J. Med."},{"key":"10.1016\/j.neuropharm.2026.111173_bib31","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.nrl.2015.06.011","article-title":"El modelo de 6-hidroxidopamina y la f isiopatolog\u00eda parkinsoniana: nuevos hallazgos en un viejo modelo","volume":"32","author":"Hernandez-Baltazar","year":"2017","journal-title":"Neurologia"},{"issue":"10","key":"10.1016\/j.neuropharm.2026.111173_bib32","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1002\/ptr.7144","article-title":"Quercetin and metabolic syndrome: a review","volume":"35","author":"Hosseini","year":"2021","journal-title":"Phytother Res."},{"issue":"Issue 2","key":"10.1016\/j.neuropharm.2026.111173_bib33","first-page":"227","article-title":"Carbohydrate ., elsevier. Biomedical applications of chitin and chitosan based nanomaterials A short review","volume":"82","author":"Jayakumar","year":"2010"},{"issue":"10","key":"10.1016\/j.neuropharm.2026.111173_bib34","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/ptr.3186","article-title":"Vitexin, orientin and other flavonoids from Spirodela polyrhiza inhibit adipogenesis in 3T3-L1 cells","volume":"24","author":"Kim","year":"2010","journal-title":"Phytother Res."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111173_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.colsurfb.2009.09.001","article-title":"Biodegradable polymeric nanoparticles based drug delivery systems","volume":"75","author":"Kumari","year":"2010","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.neuropharm.2026.111173_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176819","article-title":"Experimental models of Parkinson's disease: challenges and opportunities","volume":"980","author":"Lal","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2026.111173_bib38","article-title":"A review on medicinal prop erties of orientin","volume":"2016","author":"Lam","year":"2016","journal-title":"Adv. Pharmacol. Sci."},{"issue":"Suppl. 1","key":"10.1016\/j.neuropharm.2026.111173_bib39","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.parkreldis.2004.01.005","article-title":"Inflammation and neurodegeneration in Parkinson's disease","volume":"10","author":"McGeer","year":"2004","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.neuropharm.2026.111173_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146129","article-title":"Iron and oxidative stress in Parkinson's disease: anobservational study of injury biomarkers","volume":"11","author":"Medeiros","year":"2016","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.neuropharm.2026.111173_bib43","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3390\/pharmaceutics9040053","article-title":"An overview of chitosan nanoparticles and its application in non-parenteral drug delivery","volume":"9","author":"Mohammed","year":"2017","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111173_bib45","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2174\/138161212798918995","article-title":"Curcumin: a potential neuroprotective agent in Parkinson's disease","volume":"18","author":"Mythri","year":"2012","journal-title":"Curr. Pharm. Des."},{"issue":"6","key":"10.1016\/j.neuropharm.2026.111173_bib48","doi-asserted-by":"crossref","first-page":"248","DOI":"10.12968\/jowc.2015.24.6.245","article-title":"Chitosan membranes in a rat model of full-thickness cutaneous wounds: healing and IL-4 levels","volume":"24","author":"Nordback","year":"2015","journal-title":"J. Wound Care"},{"key":"10.1016\/j.neuropharm.2026.111173_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.595635","article-title":"Cannabidiol as a therapeutic target: evidence of its neuroprotective and neuromodulatory function in Parkinson's Disease","volume":"11","author":"Patricio","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2026.111173_bib50","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.freeradbiomed.2013.05.042","article-title":"Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse","volume":"62","author":"Perfeito","year":"2013","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.neuropharm.2026.111173_bib53","first-page":"337","article-title":"Parkinson disease","volume":"103","author":"Reich","year":"2018","journal-title":"Med. Clin."},{"key":"10.1016\/j.neuropharm.2026.111173_bib54","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1007\/s12031-021-01818-6","article-title":"Modification of glial cell activation through dendritic cell vaccination: promises for treatment of neurodegenerative diseases","volume":"71","author":"Sabahi","year":"2021","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.neuropharm.2026.111173_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115496","article-title":"GSK-3\u03b2: an exuberating neuroinflammatory mediator in Parkinson's disease","volume":"210","author":"Samim Khan","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2026.111173_bib56","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0028-3908(00)00005-8","article-title":"CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury","volume":"39","author":"Schallert","year":"2000","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.neuropharm.2026.111173_bib57","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jconrel.2011.10.006","article-title":"Modeling of diffusion controlled drug delivery","volume":"161","author":"Siepmann","year":"2012","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.neuropharm.2026.111173_bib58","article-title":"Subtle cardiovascular dysfunction in the unilateral 6-Hydroxydopamine-Lesioned rat","volume":"2010","author":"Slack","year":"2010","journal-title":"Parkinsons Dis."},{"key":"10.1016\/j.neuropharm.2026.111173_bib59","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/823206","article-title":"Cognitive-enhancing effect of quercetin in a rat model of Parkinson's disease induced by 6-hydroxydopamine","volume":"2012","author":"Sriraksa","year":"2012","journal-title":"Evid. Based Complement. Alternat. Med."},{"issue":"11","key":"10.1016\/j.neuropharm.2026.111173_bib60","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1177\/1535370215576313","article-title":"Parkinson's disease and enhanced inflammatory response","volume":"240","author":"Stojkovska","year":"2015","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.neuropharm.2026.111173_bib63","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1365-201X.1971.tb11000.x","article-title":"Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system","volume":"367","author":"Ungerstedt","year":"1971","journal-title":"Acta Physiol. Scand. Suppl."},{"key":"10.1016\/j.neuropharm.2026.111173_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2021.118617","article-title":"Bioadhesive chitosan nanoparticles: dual targeting and pharmacokinetic aspects for advanced lung cancer treatment","volume":"274","author":"Vikas","year":"2021","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.neuropharm.2026.111173_bib65","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.bbr.2015.09.024","article-title":"Protective effect of the orientin on noise-induced cognitive impairments in mice","volume":"296","author":"Wang","year":"2016","journal-title":"Behav. Brain Res."},{"issue":"10","key":"10.1016\/j.neuropharm.2026.111173_bib66","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.05.002","article-title":"Orientin Attenuates cerebral Ischemia\/Reperfusion Injury in rat model through the AQP-4 and TLR4\/NF-\u03baB\/TNF-\u03b1 signaling pathway","volume":"26","author":"Wang","year":"2017","journal-title":"J. Stroke Cerebrovasc. Dis."},{"issue":"3","key":"10.1016\/j.neuropharm.2026.111173_bib67","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.pbb.2004.08.011","article-title":"Recovery of experimental Parkinson's disease with the melatonin analogues ML-23 and S-20928 in a chronic, bilateral 6-OHDA model: a new mechanism involving antagonism of the melatonin receptor","volume":"79","author":"Willis","year":"2004","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"9","key":"10.1016\/j.neuropharm.2026.111173_bib69","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.3390\/ijms25094643","article-title":"Tyrosine hydroxylase inhibitors and dopamine receptor agonists combination therapy for Parkinson's Disease","volume":"25","author":"Yi","year":"2024","journal-title":"Int. J. Mol. Sci."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390826003485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390826003485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:56:46Z","timestamp":1792789006000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390826003485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":51,"alternative-id":["S0028390826003485"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2026.111173","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuroprotective effects of chitosan nanoparticle-loaded orientin in a 6-OHDA-induced Parkinson's disease experimental model in rats","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2026.111173","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111173"}}